The deregulated expression of lncRNA VIM-AS1 was described in type 2 diabetes mellitus [70], in gastric cancer, with a role in activating the Wnt/β-catenin pathway [71], prostate cancer [72], breast cancer [73], and many others, indicating its role in the pathogenesis of numerous diseases. Here, VIM is linked to type 2 diabetes mellitus.